Heron Therapeutics (HRTX) vs Medicinova (MNOV)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Medicinova (MNOV) has outperformed Heron Therapeutics (HRTX) over the past year, gaining 26.2% versus a loss of 73.5%. Over five years, MNOV leads with a -59.7% price change compared with -96.6% for HRTX. Heron Therapeutics is the larger company by market cap ($77.1 million vs $74.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HRTX | MNOV |
|---|---|---|
| Share price | $0.4061 | $1.52 |
| Market cap | $77.10M | $74.82M |
| 1-day change | +13.37% | -1.30% |
| YTD return | -72.45% | +17.56% |
| 1-year return | -73.47% | +26.23% |
| 5-year return | -96.62% | -59.69% |
| EPS (TTM) | $-0.18 | $-0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.58 | $3.90 |
| 52-week low | $0.26 | $1.17 |
| Distance from 52-week high | -74.30% | -61.03% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1623.71% | +442.76% |
| Average volume | 2.59M | 322.57K |
| Shares outstanding | 189.85M | 49.22M |
| Employees | 128 | 6 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNOV has outperformed HRTX by 99.7 percentage points over the past year.
About Heron Therapeutics
HRTX stock →Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About Medicinova
MNOV stock →MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
HRTX vs MNOV FAQ
Which is bigger, Heron Therapeutics or Medicinova?
Heron Therapeutics (HRTX) is larger, with a market capitalization of $77.10M compared with $74.82M for Medicinova (MNOV).
Which stock has performed better over the past year, HRTX or MNOV?
MNOV returned +26.23% over the past 12 months, compared with -73.47% for HRTX (price return, excluding dividends). Past performance does not predict future results.
Are Heron Therapeutics and Medicinova in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.